Pharma Industrial India Magazine - July - August 2024

IASST Develops New Smart Sensor to Control Drug Dosage to Manage Parkinson’s Disease Sanyou Bio Rolls Out Comprehensive Monkeypox Product Line The Institute of Advanced Study in Sci- ence and Technology (IASST), an au- tonomous institute of the Department of Science and Technology, has devel- oped an affordable, user-friendly, por- table smartphone-based optical sensor system utilizing fluorescence turn-on mechanism to instantly detect low levels of L-dopa in biological samples. This portable smartphone-based fluo - rescence turn-on sensor system assists in managing Parkinson’s disease. The sensor would help in accurately de- tecting the concentration of L-dopa in the body, thereby helping to determine the precise dosage required for effec- tive control of the disease. Parkinson’s disease is marked by a con- tinuous decrease in neuron cells, which leads to a significant reduction in do - pamine (neurotransmitter) levels in our body. L-dopa is a chemical that is con- verted to dopamine in our body and so acts as an anti-Parkinson’s drug. It helps compensate for the deficiency of dopamine. As long as the correct amount of L-dopa is administered, the disease remains manageable. However, due to the progressive nature of Parkin- son’s, as the patient ages, more L-dopa is needed to compensate for the ongo- ing loss of neurons. However, too much of the L-Dopa can cause serious side effects like dyskine- sia, gastritis, psychosis, paranoia, and orthostatic hypotension, while too little can lead to the return of Parkinson’s symptoms. Considering the critical role of the op- timum level of L-dopa in therapy, it is essential to develop a simple, cost-ef- fective, sensitive, and quick method for monitoring L-dopa in biological fluids. This simple, cost-effective, and rapid screening tool is crucial for on-spot an- alyte detection in remote areas lacking advanced equipment. By detecting whether biological sam- ples from the patient have low levels of L-Dopa, the sensor could help adjust the required dosage for effective control of the disease. Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has released a comprehen- sive product line targeting monkeypox, which includes antigens, monoclonal antibodies, and overexpression cell lines. This product line features 65 items across three main categories: 26 nat- ural epitope antigens, 28 high-affinity, high-specificity monoclonal antibodies, and 11 overexpression cell lines. These products target multiple key sites on the surface of monkeypox virus, including A29L, M1R, H3L, E8L, A35R, B6R, and critical sites such as A28L, A30L, B21R, L1R and I1L, which are vital for viral in- fection and assembly. Developed using Sanyou Bio’s propri- etary ‘over-trillion innovative antibody discovery’ platform, the monoclonal an- tibodies span multiple species, includ- ing fully human, nano, and mouse anti- bodies. These antibodies are essential for therapeutic drug development, with high-affinity nanoantibodies being par - ticularly valuable for structural analysis and bispecific research. Additionally, the entire range of antibodies, natural epitope antigens, and overexpression cell lines can be utilized in diagnostic reagents and scientific research. Dr. Lang Guojun, CEO of Sanyou Bio, emphasized the company’s rapid re- sponse capabilities, citing significant contributions during the COVID-19 pandemic. During that time, Sanyou Bio played a key role in the drug dis- covery and preclinical development of two innovative COVID-19 antibody ther- apies, which were published in leading journals such as Science and Cell Re- search, with related therapeutics ad- vancing to clinical trials. With this new monkeypox product line, Sanyou Bio aims to strengthen the de- velopment of vaccines, therapeutics, diagnostic tools and research initiatives, furthering its commitment to global pub- lic health. PRODUCT LAUNCHES PHARMA INDUSTRIALINDIA · JUL-AUG 24 29